Cannabidiol: Clinical Trials

49 trials of Cannabidiol, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

15 completed, 10 recruiting, 9 terminated, 8 unknown. 49 Phase 3, 15 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 349Completed 15, Recruiting 10, Terminated 9, Unknown 8, Withdrawn 4, Not yet recruiting 2, Active not recruiting 1
Phase 215Recruiting 4, Completed 3, Terminated 3, Unknown 3, Withdrawn 2

Follow Cannabidiol: new trials by email Literature Review of Cannabidiol trials Research Report on Cannabidiol

Trials (filtered) newest first · largest first

All 49 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Stratification and Treatment in Early Psychosis Study - PROMOTE
Cannabidiol (CBD), Placebo - Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis
Phase 3Not yet recruitingUniversity of Oxford5862026-12-012026-10-08
Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving
Cannabidiol (CBD), Placebo - Alcohol Use Disorder (AUD), Withdrawal From Addictive Substance; Detoxification
Phase 2 / Phase 3RecruitingJohns Hopkins University1052026-10-212026-11-03
Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial
Dronabinol Capsules, Epidiolex 100 mg/mL Oral Solution, Placebo Dronabinol - Opioid Use Disorder
Phase 3Not yet recruitingMontefiore Medical Center402026-10-012026-06-09
Study of Cannabidiol in Sanfilippo Syndrome
Epidiolex, Placebo - Sanfilippo Syndrome, Mucopolysaccharidosis III
Phase 2 / Phase 3RecruitingLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center352026-04-012026-09-15
Topical Cannabidiol Lotion for Pruritus Relief in Scleroderma
10% urea lotion plus 1% cannabidiol, Control - Mediciine, Systemic Sclerosis (SSc)
Phase 3RecruitingKhon Kaen University362025-11-052025-11-24
Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder
Low-Dose Cannabidiol, Placebo Matched to Moderate-Dose Cannabidiol, Moderate-Dose Cannabidiol - Generalized Anxiety Disorder (GAD), Anxiety Disorders
Phase 3RecruitingWayne State University902025-11-032026-10-21
Adjunctive Cannabidiol for Recovery From Opioid Study
Cannabidiol, Placebo - Opioid Use Disorder (OUD)
Phase 3RecruitingIcahn School of Medicine at Mount Sinai4502025-06-132026-10-01
Cannabidiol as add-on Therapy for Children With Refractory Epilepsy (CBD-uN1que), a High-quality Individualized Approach: a Series of N-of-1 Trials
Cannabidiol (CBD) oral solution, Placebo - Refractory Epilepsy in Children, Refractory Epilepsy
Phase 3RecruitingUMC Utrecht502025-02-062026-06-25
Cannabidiol's Role in Dementia Management
Cannabidiol Oil - Dementia, Vascular, Dementia, Mixed
Phase 2 / Phase 3UnknownHospital Pengajar Universiti Putra Malaysia4862024-09-012024-07-23
Evaluating Efficacy and Safety of CBD TPM Capsules for Use in Insomnia
Cannabidiol (CBD) Capsule 75mg, Placebo - Insomnia
Phase 3Active not recruitingAvecho Biotechnology5192024-05-162026-06-30
Therapy With Paravertebral Oxygen-ozone Injections and Topical Cannabidiol and β-Caryophyllene Patch in Neck Pain
Cannabidiol and β-Caryophyllene Patch, Oxygen-Ozone Therapy - Neck Pain
Phase 3UnknownHumanitas Clinical and Research Center522024-02-012023-12-13
Cannabidiol for Bipolar Depression (CBD-BD)
Cannabidiol, Placebo - Bipolar Disorder
Phase 3RecruitingUniversity of British Columbia3602023-10-152025-04-23
Alcohol Use Disorder and Cannabidiol
Cannabidiol, Placebo - Alcohol Use Disorder
Phase 2 / Phase 3RecruitingUniversity of Colorado, Denver1802023-04-302026-06-15
Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures
GWP42003-P, Placebo - Seizures Associated With EMAS
Phase 3TerminatedJazz Pharmaceuticals32022-10-312025-02-03
Cannabidiol 133mg + Cannabigerol 66mg + Tetrahydrocannabinol 4mg Vs Placebo As Adjuvant Treatment in Chronic Migraine -
Placebo oral drops, Cannabidiol + Cannabigerol + Tetrahydrocannabinol 133/66/4mg - Chronic Migraine, Headache, Overuse Headache Medication
Phase 2 / Phase 3TerminatedHospital Israelita Albert Einstein1102022-10-182025-02-24
Cannabidiol (CBD) in Pain Reduction for Knee Osteoarthritis
Cannabidiol (CBD), Placebo - Knee Arthritis
Phase 2 / Phase 3RecruitingNYU Langone Health1002022-06-222026-06-09
Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis
Cannabidiol oral solution - Early Psychosis
Phase 3RecruitingUniversity of California, San Diego1202022-06-012026-01-08
CBD (Cannabidiol)/THC (Tetrahydrocannabinol) Solution as a Pharmacological Strategy for Patients With Fibromyalgia (FibroCann)
cannabidiol and tetrahydrocannabinol, Placebo - Fibromyalgia
Phase 2 / Phase 3UnknownFG Brasil LTDA402022-04-152022-04-11
Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study
Cannabidiol (CBD) Oil Capsules, Sunflower Lecithin Oil in Capsule - Generalized Anxiety Disorder, Social Anxiety Disorder
Phase 3UnknownMcMaster University502021-12-152023-02-14
Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.
All trans-retinoic acid, 13-Cis Retinoic Acid plus Tocopherol, Mifepristone - Breast Cancer Female
Phase 3UnknownMahmoud Ramadan mohamed Elkazzaz1602021-08-012021-08-23

Showing 20 of 49. Sign in to see all of them.

Conditions studied

Epilepsy (9)  ·  Epilepsies, Myoclonic (8)  ·  Lennox Gastaut Syndrome (7)  ·  Seizures (5)  ·  Marijuana Abuse (4)  ·  Spasms, Infantile (4)  ·  Tuberous Sclerosis (3)  ·  Alcoholism (2)  ·  Anxiety Disorders (2)  ·  Bipolar Disorder (2)  ·  COVID-19 (2)  ·  Fibromyalgia (2)  ·  Generalized Anxiety Disorder (2)  ·  Opioid-Related Disorders (2)  ·  Psychotic Disorders (2)

Sponsors

Jazz Pharmaceuticals (12)  ·  INSYS Therapeutics Inc (3)  ·  University of Sao Paulo (2)  ·  Antonio Waldo Zuardi (1)  ·  Avecho Biotechnology (1)  ·  Cardiol Therapeutics Inc. (1)  ·  Colorado State University (1)  ·  FG Brasil LTDA (1)  ·  GW Research Ltd (1)  ·  Hospital Israelita Albert Einstein (1)  ·  Hospital Pengajar Universiti Putra Malaysia (1)  ·  Hospital de Clinicas de Porto Alegre (1)  ·  Humanitas Clinical and Research Center (1)  ·  Icahn School of Medicine at Mount Sinai (1)  ·  Johns Hopkins University (1)

Countries

United States (27)  ·  Spain (7)  ·  Brazil (6)  ·  Italy (6)  ·  Poland (6)  ·  United Kingdom (6)  ·  Netherlands (5)  ·  Australia (4)  ·  Canada (4)  ·  France (2)  ·  Austria (1)  ·  Denmark (1)  ·  Finland (1)  ·  Germany (1)  ·  Greece (1)

Top investigators

Neha Parikh (3)  ·  Alexandre O Kaup, MD, PhD (1)  ·  Ammaar H Abidi, DDS, PhD (1)  ·  Amr Ahmed (1)  ·  Christine Rabinak, PhD, MBA (1)  ·  Cristiano Sconza, MD (1)  ·  Darren Mansfield (1)  ·  David Woliinsky, MD (1)  ·  Deepika Slawek, MD, MPH, MS (1)  ·  Dennis McNamara, MD (1)  ·  Hilary Marusak, PhD (1)  ·  Jose A. Crippa, MD; PhD (1)  ·  Karen J Derefinko, PhD (1)  ·  Karen Stern, MD (1)

Results publications

PMID 29768152, PMID 33797076, PMID 33825230, PMID 34265088, PMID 34957550, PMID 37052803, PMID 40775196, PMID 28538134, PMID 30955420, PMID 32119035, PMID 33346789, PMID 34287833, PMID 34387679, PMID 34406656, PMID 34619044, PMID 35175622, PMID 37606606, PMID 37920963, PMID 38037108, PMID 38441854, PMID 40846590

NIH funding

2014 (5), 2015 (4), 2019 (2), 2018 (1), 2023 (1), 2025 (1), R01AA029606 (1), R34DA063987 (1), R61MH137105 (1), UH3DA050323 (1)